Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Effie Rahman

Ophthalmology Bellaire, TX Medical Doctor

NPI 1154777969 CMS profile 11253906

4460 Bissonnet St Ste 200, Bellaire, TX 77401

Open in the dashboard

General payments

$21,014

179 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$534,438 paid to institutions, not to them · program years 2023–2025

Through program year 2025, Effie Rahman of Bellaire, TX is reported in the CMS Open Payments database as having received $21,014 across 179 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $534,438 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 93rd percentile of Ophthalmology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,315 39
2024 General $12,649 73
2023 General $2,246 39
2022 General $887 10
2021 General $2,799 17
2019 General $117 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Effie Rahman
  • Ophthalmology median
  • Middle half of Ophthalmology
  • National median

In program year 2025, general payments to Effie Rahman were reported at $2,315. Among 13,034 Ophthalmology profiles paid that year, the median was $384 and the middle half received between $136 and $917.

Show as a table
Year Effie Rahman Ophthalmology median Middle half National median
2019 $117 $258 $104–$655 $163
2020 $0 $126 $45–$321 $114
2021 $2,799 $205 $76–$534 $132
2022 $887 $266 $100–$678 $149
2023 $2,246 $308 $117–$745 $160
2024 $12,649 $340 $127–$846 $164
2025 $2,315 $384 $136–$917 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Regeneron Pharmaceuticals, Inc. $4,525 17 payments
  2. Ocular Therapeutix, Inc. $3,977 4 payments
  3. EyePoint Pharmaceuticals US, Inc. $2,971 6 payments
  4. Alimera Sciences, Inc. $1,757 10 payments
  5. Bausch & Lomb, a division of Bausch Health US, LLC $1,718 14 payments
  6. Regeneron Healthcare Solutions, Inc. $1,692 41 payments
  7. Apellis Pharmaceuticals, Inc. $867 27 payments
  8. Alcon Vision LLC $602 5 payments
  9. Astellas Pharma US Inc $517 11 payments
  10. Genentech USA, Inc. $478 13 payments
  11. Other $1,909 31 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $10,130 7 payments
  2. Food and Beverage $8,251 163 payments
  3. Honoraria $1,390 1 payment
  4. Travel and Lodging $1,242 8 payments
Products named General payments · program years 2019–2025
  1. EYLEA HD $5,172 41 payments
  2. EYP-1901 $1,949 2 payments
  3. OPHTHALMIC INSTRUMENTS $1,718 14 payments
  4. STELLARIS $1,718 14 payments
  5. Bausch + Lomb $1,718 14 payments
  6. ILUVIEN $1,601 10 payments
  7. YUTIQ Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye $1,535 7 payments
  8. EYLEA $1,193 18 payments
  9. YUTIQ Chronic Non-infectious Posterior Segment Uveitis $1,005 3 payments
  10. VABYSMO $748 16 payments
  11. Other $2,969 61 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

430

Median for Ophthalmology: 891

Drug cost

$12,262

Median for Ophthalmology: $68,233

Branded share of claims

26%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Prednisolone Acetate Generic 138 $7,705
Moxifloxacin Moxifloxacin Hcl Brand 63 $1,538
Ketorolac Tromethamine Generic 47 $902
Atropine Sulfate Generic 18 $551
Timolol Maleate Generic 50 $513
Erythromycin Erythromycin Base Brand 49 $443
Brimonidine Tartrate Generic 41 $395
Cyclopentolate Hcl Generic 11 $172
Latanoprost Generic 13 $42

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 46 billing codes

Paid by Medicare

$2,043,447

Of which drugs: $1,690,706

Medicare patients

722

Average age 76

Services billed

13,487

419 women, 303 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 44%
Diabetes 39%
Ischemic heart disease 35%
Chronic kidney disease 30%
Heart failure 20%
Atrial fibrillation 18%
Depression 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, aflibercept, 1 mg J0178 Office 183 1,438 $940,402
Injection, aflibercept hd, 1 mg J0177 Office 56 1,024 $268,985
Injection, pegcetacoplan, intravitreal, 1 mg J2781 Office 42 1,485 $173,724
Injection, faricimab-svoa, 0.1 mg J2777 Office 25 4,801 $131,919
Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg Q5128 Office 48 668 $119,375
Injection, ranibizumab, 0.1 mg J2778 Office 24 220 $26,746

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 11 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
EYLEA HD
  • Regeneron Pharmaceuticals, Inc. $3,883
  • Regeneron Healthcare Solutions, Inc. $449
$4,332 — 1,024
ILUVIEN
  • Alimera Sciences, Inc. $767
$767 — —
Syfovre
  • Apellis Pharmaceuticals, Inc. $380
$380 — 1,485
VABYSMO
  • Genentech USA, Inc. $231
  • Genentech, Inc. $18
$249 — 4,801
DEXTENZA
  • Ocular Therapeutix, Inc. $217
$217 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 11 in the dashboard with a free account

Records

179 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Ophthalmology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record